Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Catherine Martre | F | - |
Meletios Therapeutics SAS
 Meletios Therapeutics SAS BiotechnologyHealth Technology Meletios Therapeutics SAS is a French biotech company founded in 2020 by a team of high level scientists and experienced biotech managers. The company is based in Lyon, France. The company's aim is to fulfill the urgent and large unmet medical need for broad spectrum treatments against current and emerging viral infections. One of their first drug candidates has confirmed its broad-spectrum potential. Catherine Martre has been the CEO of the company since 2021. | 3 years |
| Alexandre Mouradian | M | 54 |
Meletios Therapeutics SAS
Meletios Therapeutics SAS BiotechnologyHealth Technology Meletios Therapeutics SAS is a French biotech company founded in 2020 by a team of high level scientists and experienced biotech managers. The company is based in Lyon, France. The company's aim is to fulfill the urgent and large unmet medical need for broad spectrum treatments against current and emerging viral infections. One of their first drug candidates has confirmed its broad-spectrum potential. Catherine Martre has been the CEO of the company since 2021. | - |
| Rodolphe Besserve | M | 51 |
Meletios Therapeutics SAS
Meletios Therapeutics SAS BiotechnologyHealth Technology Meletios Therapeutics SAS is a French biotech company founded in 2020 by a team of high level scientists and experienced biotech managers. The company is based in Lyon, France. The company's aim is to fulfill the urgent and large unmet medical need for broad spectrum treatments against current and emerging viral infections. One of their first drug candidates has confirmed its broad-spectrum potential. Catherine Martre has been the CEO of the company since 2021. | - |
| Gérard Le Fur | M | 73 |
Meletios Therapeutics SAS
Meletios Therapeutics SAS BiotechnologyHealth Technology Meletios Therapeutics SAS is a French biotech company founded in 2020 by a team of high level scientists and experienced biotech managers. The company is based in Lyon, France. The company's aim is to fulfill the urgent and large unmet medical need for broad spectrum treatments against current and emerging viral infections. One of their first drug candidates has confirmed its broad-spectrum potential. Catherine Martre has been the CEO of the company since 2021. | - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| France | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Patrice Garnier
- Personal Network
